The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I know it's early but this does seem a somewhat muted response to what I see as great news.
Revenue producer ... good. New stream ...
Strikes me this is separate product to the development agreement announced with Abnova and Coastal Genomics.Genomics in previous RNS. In which case we could see potentially 2 more of these by y/e
New product offering in cancer and hitting the ground with £1M revenue.
Freaking excellent. Back to the mid teens ?
$1 million of next 6-12 months is great news - swift step up in income for NIPT
NGS testing in oncology ... that’ll do nicely!!
What RNS? I can’t see one?
Hopefully the start of our re-rate.
Here was I wondering why the sp recovered from that low yesterday . . . .
So now we know how Reynolds managed to place £3m in short order.
You're completely right as ever A new CEO who obtained 10m shares in options, botched what should have been a simple placing after a long running legal dispute which should have seen the sp spike, will then walk into an AGM and say I don't have a plan. He will then follow that up and default and say I will just use the one which was developed by the last CEO failing to appreciate he was essentially kicked upstairs to a vice chairman role Having considered that insightful insight I agree
Boyzee - don't torture yourself, your looking too severely into what is natural procedure. No reason other than opportunity to buy at placing price. Lets see what happens on the 25th, we all might be pleasantly surprised.
RNS last Friday said strategic review would be released this calendar year, can’t see it being in next 2 weeks?
Going through the trades today ...nice round blocks ... smells like 2 ii.s trading away merrily ...
Hi Florida. I take your point about being held in the placing zone. However, the placing woukd have bn touted maybe back at 15p... now at 10pish. It.s turned into a juicy dilution. The sp has fallen too far in % tetms for such a paltry raise. Maybe the mkt is looming at the recent revenues ...the last 6months ...and going fwd. Hope they are wrong. Of course, the next dilution is now being factored in, some already gone short i.m sure. Just my unfortunate thoughts ...
Couldn't resist.
Traditionally the price is held within the placing zone (10p) until all shares are submitted (25th Oct). This is by no means a given, however, realistically I can't see this moving either way for the next three weeks. There will be a concerted effort to push this down to 9p, at which point I will be expending the last of my spare cash. What's interesting is the date of the AGM, curiously on the same day the shares are issued. Could be an announcement of sorts having then acquired support from the market to push the price forward.
It has been discussed recently and does seem to be of concern to some whether the product (NIPT) could be superseded. The percentage accuracy of nipt is imv a preventative measure in it's own right, however, if Illumina or anyone else decided to equal or better Premaitha's NIPT product they would have to come up with a completely novel or new idea to avoid infringing on Premaitha's patent. The settlement deal was achieved in part because there was literally no way to compete. So there you have it, two fighting giants showing interest in little old Premaitha, not because they were sold on the hype of the company when it was first listed, but simply because the product could not be beaten.
To your credit Dibs61 that's quite an interesting point, unfortunately takeovers are not inherited they are propagated from events and changes within a company that are seen by a potential buyer in a new light. For sure the game has now changed and we are in a completely different environment to that point at which litigation ruled. So it does make that opportunity more likely. Moving on, changes to the internal structure of the company can build on the established interest already undertaken by a potential buyer. Recent BOD changes are already part of that structural re-processing and imv vital for the company to move forward at the pace required. The pace of acceleration will determine at which point a buyer might decide to jump in. Imv, if it's going to happen it will be around the time of the next figures.
Looks like buying pressure ...but do you really trust the buy/sell ratio with a falling sp. Nope. Due to the largish bid/offer spread the mm.s will be taking the moycull.
who felt a bit 'cheated' not being involved in the placing can now join in, just like the last one at 4.5p.Let's hope it can appreciate the same (or more) from here.Plenty of buying pressure it seems, but MM not budging atm?
When talk of take overs is being banded around its worth remembering that Life Technologies Limited which was acquired by TF in 2014 hold 95,688,706 warrants here exercisable above, around and below the current SP. Thats approx 25% of the current share capital.
Hypothetically what would have to happen is that the company would be split beforehand. Premaitha already operates as a Group company. So I believe YourGene was bought in a largely share swap (+£500k) by Premaitha Health Plc (Company No. 03971582) which is a subsidiary of Premaitha Ltd (Company No. 08436676). The BoD that you see on the website are for Premaitha Health. Only Dr Little and Barry Hexthall (CFO) are Directors of Premaitha Ltd.
Premaitha Health operate under the same trading name within EU and as YourGene Health outside EU. So - hypothetically - if the company was to be split and sold along those lines (based on different sequencer platforms) that makes sense with TMO picking up YourGene Health. It would be interesting to see in the coming months if this is formalised via any restructuring.
However as explained this is just a hypothesis of mine which Florida probably would have some comments upon. Key thing would be the strategic review that the CEO I suspect will publish in the next 2 weeks and explored in a comprehensive Hardman report. It will be interesting then to see what the sales for FY2019 will then be expected and whether a 2nd placing is indeed required. Let's see. But then its anyone's guess whether a TO would await the end of the strategy or not.
The good thing is that the BoD already has enough numbers to cover any potential restructuring. We have a Chairman and Vice Chairman. On the commercial and business development side you have Nick Claxton (Chief Commercial Officer) Peter Collins (Chief Business Officer) now Hayden Jeffreys (Group Commercial Director)..so not short of people.
Agree Twix. Current sp and narrative of last 2 weeks is an absolute surreal (and very unpleasant) experience for LTHs these past 3 years. That said this month after the dust settles should be interesting.
For TO I guess TMO and Illumina can split the company between them accordingly...?
Hope illumina are being generous with the nipt tech purchases.Will our current /recent sales be enough to ensure revenue builds up at previous good rates. Need we be wsry of the last 6 months ? Yes. Further out we should be okay, but sales lag on illumina platform wont help. We.ll need more cash to fill the time gap. I guess this is what pi.s are thinking? Are we now a genuine TO for some wealthy corp? MM.s doing there stuff. Many pi.s will bail given the recent rise from 7p to 15p ... welcome to the Aim Circus ...
Opportunity at AGM to ask what year will shareholder value deliver on the promised bright future described at each of the previous AGM's?
Hi Flipper ... the shorts closing idea didnt really pan out. There may have bn some short closing, and indeed some more to come, but the reality is there.s not been much action except on opening yesterday. Needs to stabilise. The mm.s will push for 10p. Shares not admitted yet either ...altho their dilution, is only 5-6% if i recall correctly. Kp the faith ...